2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
275
Carcinoma, Intraductal, Noninfiltrating
25
Breast Carcinoma In Situ
21
Neoplasm Metastasis
14
Neoplasms
13
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Endometrial Neoplasms
6
Prostatic Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Recurrence
3
Obesity
3
Hot Flashes
3
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sleep Wake Disorders
2
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Interventions
testosterone undecanoate
4
Testosterone
3
Alendronate
2
testosterone 17 beta-cypionate
1
Triptorelin Pamoate
1
Testosterone Propionate
1
Tamoxifen
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Practice Guidelines as Topic
1
Pioglitazone
1
Orchiectomy
1
Observation
1
Methyltestosterone
1
Mental Status and Dementia Tests
1
Gonadotropin-Releasing Hormone
1
Gels
1
Drug Evaluation
1
Clomiphene
1
Castor Oil
1
Blood Specimen Collection
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypogonadism
×
Tamoxifen
×
Clear all
NCT07535905
2026-04-17
REVIVE
University Health Network, Toronto
Phase 2
Not yet recruiting
96 enrolled